Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
A phase 3 trial of Camrelizumab and Rivoceranib (apatinib) in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC is a phase 3 interventional study registered as NCT04342910 by Jiangsu HengRui Medicine Co., Ltd., with 550 participants planned, started 2020-09-21 and due to reach its primary completion in 2026-04-01. Interventions recorded: camrelizumab, Apatinib Mesylate, Paclitaxel and Irinotecan.
Similar pages
not linked directly; found by shared links- TrialCamrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialStudy to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Shares Rivoceranib (apatinib), Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialClinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSafety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
- TrialSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.